West Pharmaceutical Services, Inc. (WST) Guidance & Earnings Results

On 2026-07-23 West Pharmaceutical Services, Inc. raised guidance: "FY26 net sales raised to $3.345-3.380B from $3.295-3.350B; FY26 adjusted-diluted EPS raised to $8.85-9.05 from $8.40-8.75; Q3 net sales $820-835M; Q3 adjusted-diluted EPS $2.14-2.24; FY26 capex $250-275M…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

WSTWest Pharmaceutical Services, Inc.Follow WST — free

Medical Instruments & Supplies · Healthcare

—

Price chart with a free account

Market cap: 27.6B
P/E TTM: 50.2
Dividend yield: 0.2%
52-week: —
Next earnings: 29 Oct, in 5 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
23 Jul 26	Raised	FY26 net sales raised to $3.345-3.380B from $3.295-3.350B; FY26 adjusted-diluted EPS raised to $8.85-9.05 from $8.40-8.75; Q3 net sales $820-835M; Q3 adjusted-diluted EPS $2.14-2.24; FY26 capex $250-275M (unchanged) · full year
23 Apr 26	Raised	FY2026 revenue raised to $3.295B-$3.350B; adjusted EPS raised to $8.40-$8.75 · full year
12 Feb 26	Raised	FY2026 net sales growth 4.6%-6.5%, adjusted EPS growth 7.7%-12.5%
23 Oct 25	Raised	FY2025 net sales guidance raised to $3.060-3.070B; adjusted EPS to $7.06-7.11 · full year
24 Jul 25	Raised	FY25 net sales raised to $3.040-3.060B from $2.945-2.975B; FY25 adjusted-diluted EPS raised to $6.65-6.85 from $6.15-6.35; organic net sales growth raised to ~3-3.75% from 2-3%; capex unchanged at $275M · full year

West Pharmaceutical Services, Inc. — questions

What guidance did West Pharmaceutical Services, Inc. give?: On 2026-07-23: "FY26 net sales raised to $3.345-3.380B from $3.295-3.350B; FY26 adjusted-diluted EPS raised to $8.85-9.05 from $8.40-8.75; Q3 net sales $820-835M; Q3 adjusted-diluted EPS $2.14-2.24; FY26 capex $250-275M (unchanged)"
When does West Pharmaceutical Services, Inc. report earnings?: West Pharmaceutical Services, Inc.'s next earnings report is expected on 2026-10-29.

Every figure on this page comes from West Pharmaceutical Services, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.